BioPharma DiveOriginal article
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
NDA FilingetentamigPositive
AI Analysis
Summary
AbbVie is advancing etentamig, a dual-acting myeloma drug, toward FDA submission, positioning it against competitors from J&J, Pfizer, and Regeneron based on a favorable side effect profile.
Outcome Details
AbbVie pushing etentamig toward FDA submission with improved side effect profile versus competitors
Importance:6/10
Sentiment:
0.60
myelomadual-acting mechanismFDA submissioncompetitive advantageside effect profile
Related Companies
Read the original article
Published by BioPharma Dive on September 4, 2026 4:00 PM